NCT01623479已完成不适用
An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 585
- 主要终点
- Percentage of Subjects Satisfied With Latisse®
研究概览
简要总结
This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypotrichosis of the eyelashes
- •Using bimatoprost ophthalmic solution 0.03% (Latisse®) for at least 12 months
排除标准
- •Use of any over-the-counter medication(s) for eyelash growth
研究组 & 干预措施
Hypotrichosis of the Eyelashes
Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
干预措施: bimatoprost 0.03% (Drug)
结局指标
主要结局
Percentage of Subjects Satisfied With Latisse®
时间窗: Day 1
Overall subject satisfaction with Latisse® was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.
次要结局
- Number of Applications of Latisse® Per Week(Day 1)
- Percentage of Subjects Satisfied Wtih Their Eyelashes(Day 1)
研究者
相似试验
已完成
3 期
Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid MarginHypotrichosisNCT00907426Allergan368
已完成
2 期
A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00538304Allergan222
已完成
4 期
Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT01298700Allergan806
已完成
4 期
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in ChildrenEyelash HypotrichosisAlopecia AreataNCT01023841Allergan71
已完成
4 期
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to LatanoprostGlaucomaNCT00347841Innovative Medical